Patient disposition
| n (%) . | Ruxolitinib plus siremadlin 20 mg (n = 7) . | Ruxolitinib plus siremadlin 30 mg (n = 10) . | Ruxolitinib plus siremadlin 40 mg (n = 6) . | Ruxolitinib plus siremadlin total (N = 23) . |
|---|---|---|---|---|
| Treated | 7 (100) | 10 (100) | 6 (100) | 23 (100) |
| Treatment ongoing∗ | 1 (14.3) | 1 (10.0) | 1 (16.7) | 3 (13.0) |
| Discontinued from treatment | 6 (85.7) | 9 (90.0) | 5 (83.3) | 20 (87.0) |
| Reason for discontinuation | ||||
| Adverse event | 3 (42.9) | 5 (50.0) | 2 (33.3) | 10 (43.5) |
| Physician decision | 3 (42.9) | 3 (30.0) | 1 (16.7) | 7 (30.4) |
| Progressive disease | 0 | 1 (10.0) | 1 (16.7) | 2 (8.7) |
| Patient decision | 0 | 0 | 1 (16.7) | 1 (4.3) |
| Death | 0 | 0 | 0 | 0 |
| Protocol deviation | 0 | 0 | 0 | 0 |
| Completed the study | 5 (71.4) | 8 (80.0) | 2 (33.3) | 15 (65.2) |
| Discontinued from the study | 1 (14.3) | 1 (10.0) | 3 (50.0) | 5 (21.7) |
| Reason for discontinuation | ||||
| Patient decision | 0 | 0 | 0 | 0 |
| Death | 0 | 0 | 3 (50.0) | 3 (13.0) |
| Physician decision | 1 (14.3) | 1 (10.0) | 0 | 2 (8.7) |
| Adverse event | 0 | 0 | 0 | 0 |
| New therapy for study indication | 0 | 0 | 0 | 0 |
| n (%) . | Ruxolitinib plus siremadlin 20 mg (n = 7) . | Ruxolitinib plus siremadlin 30 mg (n = 10) . | Ruxolitinib plus siremadlin 40 mg (n = 6) . | Ruxolitinib plus siremadlin total (N = 23) . |
|---|---|---|---|---|
| Treated | 7 (100) | 10 (100) | 6 (100) | 23 (100) |
| Treatment ongoing∗ | 1 (14.3) | 1 (10.0) | 1 (16.7) | 3 (13.0) |
| Discontinued from treatment | 6 (85.7) | 9 (90.0) | 5 (83.3) | 20 (87.0) |
| Reason for discontinuation | ||||
| Adverse event | 3 (42.9) | 5 (50.0) | 2 (33.3) | 10 (43.5) |
| Physician decision | 3 (42.9) | 3 (30.0) | 1 (16.7) | 7 (30.4) |
| Progressive disease | 0 | 1 (10.0) | 1 (16.7) | 2 (8.7) |
| Patient decision | 0 | 0 | 1 (16.7) | 1 (4.3) |
| Death | 0 | 0 | 0 | 0 |
| Protocol deviation | 0 | 0 | 0 | 0 |
| Completed the study | 5 (71.4) | 8 (80.0) | 2 (33.3) | 15 (65.2) |
| Discontinued from the study | 1 (14.3) | 1 (10.0) | 3 (50.0) | 5 (21.7) |
| Reason for discontinuation | ||||
| Patient decision | 0 | 0 | 0 | 0 |
| Death | 0 | 0 | 3 (50.0) | 3 (13.0) |
| Physician decision | 1 (14.3) | 1 (10.0) | 0 | 2 (8.7) |
| Adverse event | 0 | 0 | 0 | 0 |
| New therapy for study indication | 0 | 0 | 0 | 0 |
Ongoing at the time of the data cutoff date, 16 March 2023. Patients completed the core phase and entered the extension phase.